Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020657 · ClinicalTrials.gov registry record · Phase 3
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
A Phase 3 study, sponsored by Gary Morrow.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00020657: Completed Phase 3 study, sponsored by Gary Morrow.
NCT00020657 is a Phase 3 study that has completed, run by Gary Morrow. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020657, a Phase 3 study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG ondansetron
- DRUG dolasetron mesylate
- DRUG granisetron hydrochloride
- DRUG prochlorperazine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
What the finished NCT00020657 record still lists
NCT00020657 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which quality-of-life assessment is the first listed.
NCT00020657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020657 about?
NCT00020657 is a clinical study titled "Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer". RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
What is the current status of trial NCT00020657?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-07. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00020657?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), ondansetron (DRUG), dolasetron mesylate (DRUG), granisetron hydrochloride (DRUG), prochlorperazine (DRUG).
Who is sponsoring clinical trial NCT00020657?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia